DOI:
10.1055/s-00000007
Aktuelle Urologie
LinksClose Window
References
Motzer RJ, Escudier B, McDermott DF. et al.
Survival outcomes and independent response assessment with nivolumab plus ipilimumab versus sunitinib in patients with advanced renal cell carcinoma: 42-month follow-up of a randomized phase 3 clinical trial.
J Immunother Cancer 2020;
8: e000891
DOI: 10.1136/jitc-2020-000891. (PMID: 32661118)
Access:
Access:
We do not assume any responsibility for the contents of the web pages of other providers.